1. Scrip
  2. >>R&D

Sickle Cell Data Show Value Of Novartis’s Recently Acquired SEG101

 
• By Mandy Jackson

Phase II SUSTAIN data presented at ASH show a statistically significant reduction in sickle cell pain crises for SEG101 (crizanlizumab), a potential blockbuster for Novartis, which recently said it will pay up to $665m for the antibody’s developer.

Novartis AG’s recently acquired monoclonal antibody SEG101 showed a statistically significant reduction in sickle cell pain crises at the antibody’s highest dose in the Phase II SUSTAIN clinical trial, which one analyst said could generate $1bn or more in annual revenue given the high unmet need for the hereditary disease.

The company has not indicated when it will begin a Phase III program for SEG101 (crizanlizumab; formerly SelG1), which inhibits p-selectin, but Novartis told Scrip that it “will continue the development of SEG101 and will consult with relevant health authorities to discuss timelines.” The most advanced selectin inhibitor in development for sickle cell disease (SCD) is Pfizer Inc

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Scrip

In Brief: Genmab To Seek FDA Nod For Epkinly In Lymphoma

 
• By Sushmita Panda

Genmab will submit an sBLA for Epkinly in R/R follicular lymphoma in H1 2025, backed by positive Phase III data.

Pharma Predicts Modest Impact From Tariffs, But It Depends On What Comes Next

 
• By Jessica Merrill

Drugmakers aren’t expecting a big financial hit from tariffs for now, but a report commissioned by PhRMA suggests the cost of pharma-sector tariffs could be steep.

OPPI’s Matai On Section 3(d) Of India’s Patent Regulations: Now’s The Time To Open Up

 
• By Anju Ghangurde

Anil Matai, director general, Organization of Pharmaceutical Producers of India, talks in this audio interview about the evolving intellectual property landscape in India post the 2024 amendments, including long-standing sticking points such as Section 3(d) of India’s patent regulations and innovator firms' experience of the Bolar provision. There’s also a "compelling reason" to consider regulatory data protection, he claims.